Cationic manganese (Mn)-substituted N-pyridylporphyrin-based potent mimics of the family of superoxide dismutases (SODs) protect normal tissues from injury related to ionizing radiation (IR) by reducing levels of reactive oxygen and nitrogen species (ROS/RNS). Furthermore, Mn-porphyrins have demonstrated antitumor and radiosensitizing effects on cancer cells by promoting IR-induced tumor vasculature damage and apoptotic processes. In this study, we explored the underlying mechanisms of Mn-porphyrin-mediated tumor radiosensitization using murine mammary carcinoma 4T1 and melanoma B16 cells in vitro and in vivo.
Results:
Combination treatment with MnTnHex-2-PyP and IR substantially reduced cell viability, clonogenic cell survival, and DNA damage repair and synergistically increased IR-induced apoptosis of 4T1 and B16 cells. MnTnHex-2-PyP in combination with IR caused a significant delay in growth of 4T1 and B16 xenograft tumors. MnTnHex-2-PyP dose-dependently enhanced IR-mediated production of H2O2-derived species, but not superoxide. Catalase overexpression reversed MnTnHex-2-PyP-enhanced ROS production and apoptosis. Demonstrated suppression of phosphorylation of several mitogen-activated protein (MAP) kinases and activation of NF-κB by MnTnHex-2-PyP/IR, which presumably inhibited activation of the antiapoptotic pathway, are in agreement with our other data on the apoptosis of cancer cells.
Innovation and Conclusions:
MnTnHex-2-PyP exerted a radiosensitizing effect on 4T1 and B16 tumor models in vitro and in vivo via pro-oxidative actions and therefore bears a large therapeutic potential. When combined with IR, it attenuated DNA damage repair and triggered a shift from prosurvival pathways to apoptotic cell death, likely due to increased ROS production and disturbed cellular redox balance, acting at the level of nuclear factor κB (NF-κB). Antioxid. Redox Signal. 27, 1067–1082.
Get full access to this article
View all access options for this article.
References
1.
AshcraftKA, BossMK, TovmasyanA, Roy ChoudhuryK, FontanellaAN, YoungKH, PalmerGM, BirerSR, LandonCD, ParkW, DasSK, WeitnerT, ShengH, WarnerDS, BrizelDM, SpasojevicI, Batinic-HaberleI, and DewhirstMW. Novel manganese-porphyrin superoxide dismutase-mimetic widens the therapeutic margin in a preclinical head and neck cancer model. Int J Radiat Oncol Biol Phys, 93: 892–900, 2015.
2.
Batinic-HaberleI, RajicZ, TovmasyanA, ReboucasJS, YeX, LeongKW, DewhirstMW, VujaskovicZ, BenovL, and SpasojevicI. Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics. Free Radic Biol Med, 51: 1035–1053, 2011.
3.
Batinic-HaberleI, TovmasyanA, RobertsER, VujaskovicZ, LeongKW, and SpasojevicI. SOD therapeutics: Latest insights into their structure-activity relationships and impact on the cellular redox-based signaling pathways. Antioxid Redox Signal, 20: 2372–2415, 2014.
4.
Batinic-HaberleI, TovmasyanA, and SpasojevicI. An educational overview of the chemistry, biochemistry and therapeutic aspects of Mn porphyrins—From superoxide dismutation to H2O2-driven pathways. Redox Biol, 5: 43–65, 2015.
5.
Batinic-HaberleI, TovmasyanA, and SpasojevicI. Mn porphyrin-based redox-active therapeutics. In: Redox-Active Therapeutics, Oxidative Stress in Applied Basic Research and Clinical Practice, edited by Batinic-HaberleI, ReboucasJS, and SpasojevicI. Basel: Springer International Publishing, 2016, pp. 165–212.
6.
BeggAC, StewartFA, and VensC. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer, 11: 239–253, 2011.
7.
BryanHK, OlayanjuA, GoldringCE, and ParkBK. The Nrf2 cell defence pathway: keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol, 85: 705–717, 2013.
8.
Bueno-JaniceJC, TovmasyanA, and Batinic-HaberleI. Comprehensive study of GPx activity of different classes of redox-active therapeutics – Implications for their therapeutic actions. Free Radic Biol Med, 87: S86–S87, 2015.
9.
CarrollD, ZhaoY, Batinic-HaberleI, and St ClairD. A novel redox-based approach to myelodysplastic syndrome (MDS) therapy. Free Radic Biol Med, 87: S87, 2015.
10.
ChaurasiaM, BhattAN, DasA, DwarakanathBS, and SharmaK. Radiation-induced autophagy: Mechanisms and consequences. Free Radic Res, 50: 273–290, 2016.
11.
DoniaM, McCubreyJA, BendtzenK, and NicolettiF. Potential use of rapamycin in HIV infection. Br J Clin Pharmacol, 70: 784–793, 2010.
12.
DoraiT, FishmanAI, DingC, Batinic-HaberleI, GoldfarbDS, and GrassoM. Amelioration of renal ischemia-reperfusion injury with a novel protective cocktail. J Urol, 186: 2448–2454, 2011.
13.
EomKY, ChoBJ, ChoiEJ, KimJH, ChieEK, WuHG, KimIH, PaekSH, KimJS, and KimIA. The effect of chemoradiotherapy with SRC tyrosine kinase inhibitor, PP2 and temozolomide on malignant glioma cells in vitro and in vivo. Cancer Res Treat, 48: 687–697, 2016.
14.
EpperlyMW, BrayJA, KragerS, BerryLM, GoodingW, EngelhardtJF, ZwackaR, TravisEL, and GreenbergerJS. Intratracheal injection of adenovirus containing the human MnSOD transgene protects athymic nude mice from irradiation-induced organizing alveolitis. Int J Radiat Oncol Biol Phys, 43: 169–181, 1999.
15.
EvansMK, TovmasyanA, Batinic-HaberleI, and DeviGR. Mn porphyrin in combination with ascorbate acts as a pro-oxidant and mediates caspase-independent cancer cell death. Free Radic Biol Med, 68: 302–314, 2014.
16.
FrankenNA, RodermondHM, StapJ, HavemanJ, and van BreeC. Clonogenic assay of cells in vitro. Nat Protoc, 1: 2315–2319, 2006.
17.
Gauter-FleckensteinB, FleckensteinK, OwzarK, JiangC, Batinic-HaberleI, and VujaskovicZ. Comparison of two Mn porphyrin-based mimics of superoxide dismutase in pulmonary radioprotection. Free Radic Biol Med, 44: 982–989, 2008.
18.
Gauter-FleckensteinB, ReboucasJS, FleckensteinK, TovmasyanA, OwzarK, JiangC, Batinic-HaberleI, and VujaskovicZ. Robust rat pulmonary radioprotection by a lipophilic Mn N-alkylpyridylporphyrin, MnTnHex-2-PyP(5+). Redox Biol, 2: 400–410, 2014.
19.
GoYM, RoedeJR, WalkerDI, DuongDM, SeyfriedNT, OrrM, LiangY, PennellKD, and JonesDP. Selective targeting of the cysteine proteome by thioredoxin and glutathione redox systems. Mol Cell Proteomics, 12: 3285–3296, 2013.
20.
Gonzalez-ReyesS, Guzman-BeltranS, Medina-CamposON, and Pedraza-ChaverriJ. Curcumin pretreatment induces Nrf2 and an antioxidant response and prevents hemin-induced toxicity in primary cultures of cerebellar granule neurons of rats. Oxid Med Cell Longev, 2013: 801418, 2013.
21.
GreenwaldMB, AnziS, Ben SassonS, Bianco-PeledH, and KohenR. Can nitroxides evoke the Keap1-Nrf2-ARE pathway in skin?. Free Radic Biol Med, 77: 258–269, 2014.
22.
HagemannT, LawrenceT, McNeishI, CharlesKA, KulbeH, ThompsonRG, RobinsonSC, and BalkwillFR. “Re-educating” tumor-associated macrophages by targeting NF-kappa B. J Exp Med, 205: 1261–1268, 2008.
23.
HawkinsAJ, GoldingSE, KhalilA, and ValerieK. DNA double-strand break – Induced pro-survival signaling. Radiother Oncol, 101: 13–17, 2011.
24.
HolleyAK, MiaoL, St ClairDK, and St ClairWH. Redox-modulated phenomena and radiation therapy: the central role of superoxide dismutases. Antioxid Redox Signal, 20: 1567–1589, 2014.
25.
HongBJ, KimJ, JeongH, BokS, KimYE, and AhnGO. Tumor hypoxia and reoxygenation: the yin and yang for radiotherapy. Radiat Oncol J, 34: 239–249, 2016.
26.
HosseinimehrSJ. The protective effects of trace elements against side effects induced by ionizing radiation. Radiat Oncol J, 33: 66–74, 2015.
27.
JaramilloMC, BriehlMM, Batinic-HaberleI, and TomeME. Manganese (III) meso-tetrakis N-ethylpyridinium-2-yl porphyrin acts as a pro-oxidant to inhibit electron transport chain proteins, modulate bioenergetics, and enhance the response to chemotherapy in lymphoma cells. Free Radic Biol Med, 83: 89–100, 2015.
28.
JaramilloMC, BriehlMM, CrapoJD, Batinic-HaberleI, and TomeME. Manganese porphyrin, MnTE-2-PyP5+, acts as a pro-oxidant to potentiate glucocorticoid-induced apoptosis in lymphoma cells. Free Radic Biol Med, 52: 1272–1284, 2012.
29.
KangSK, RabbaniZN, FolzRJ, GolsonML, HuangH, YuD, SamulskiTS, DewhirstMW, AnscherMS, and VujaskovicZ. Overexpression of extracellular superoxide dismutase protects mice from radiation-induced lung injury. Int J Radiat Oncol Biol Phys, 57: 1056–1066, 2003.
30.
KimJH, MoonSH, NoM, KimJJ, ChoiEJ, ChoBJ, KimJS, KimIH, and KimIA. Isotype-specific inhibition of histone deacetylases: Identification of optimal targets for radiosensitization. Cancer Res Treat, 48: 1130–1140, 2016.
31.
KooT and KimIA. Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment. Radiat Oncol J, 34: 1–9, 2016.
32.
KooT and KimIA. Radiotherapy and immune checkpoint blockades: A snapshot in 2016. Radiat Oncol J, 34: 250–259, 2016.
33.
KosmacekEA, ChatterjeeA, TongQ, LinC, and Oberley-DeeganRE. MnTnBuOE-2-PyP protects normal colorectal fibroblasts from radiation damage and simultaneously enhances radio/chemotherapeutic killing of colorectal cancer cells. Oncotarget, 7: 34532–34545, 2016.
34.
LiauwSL, ConnellPP, and WeichselbaumRR. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med, 5: 173sr2, 2013.
35.
Maksimovic-IvanicD, MijatovicS, HarhajiL, MiljkovicD, DabideenD, Fan ChengK, ManganoK, MalaponteG, Al-AbedY, LibraM, GarottaG, NicolettiF, and Stosic-GrujicicS. Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo. Mol Cancer Ther, 7: 510–520, 2008.
36.
Maksimovic-IvanicD, Stosic-GrujicicS, NicolettiF, and MijatovicS. Resistance to TRAIL and how to surmount it. Immunol Res, 52: 157–168, 2012.
37.
McCubreyJA, SteelmanLS, ChappellWH, AbramsSL, FranklinRA, MontaltoG, CervelloM, LibraM, CandidoS, MalaponteG, MazzarinoMC, FagoneP, NicolettiF, BaseckeJ, MijatovicS, Maksimovic-IvanicD, MilellaM, TafuriA, ChiariniF, EvangelistiC, CoccoL, and MartelliAM. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance. Oncotarget, 3: 1068–1111, 2012.
MijatovicS, Maksimovic-IvanicD, TimotijevicG, MiljkovicD, DoniaM, LibraM, CocoM, McCubreyJ, Al-AbedY, KoracA, Stosic-GrujicicS, and NicolettiF. Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO. Free Radic Biol Med, 48: 1090–1099, 2010.
40.
ModingEJ, KastanMB, and KirschDG. Strategies for optimizing the response of cancer and normal tissues to radiation. Nat Rev Drug Discov, 12: 526–542, 2013.
41.
MoellerBJ, Batinic-HaberleI, SpasojevicI, RabbaniZN, AnscherMS, VujaskovicZ, and DewhirstMW. A manganese porphyrin superoxide dismutase mimetic enhances tumor radioresponsiveness. Int J Radiat Oncol Biol Phys, 63: 545–552, 2005.
42.
MunshiA and RameshR. Mitogen-activated protein kinases and their role in radiation response. Genes Cancer, 4: 401–408, 2013.
43.
NairS, DohST, ChanJY, KongAN, and CaiL. Regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis. Br J Cancer, 99: 2070–2082, 2008.
44.
NicolettiF, FagoneP, MeroniP, McCubreyJ, and BendtzenK. mTOR as a multifunctional therapeutic target in HIV infection. Drug Discov Today, 16: 715–721, 2011.
45.
OstmanA, FrijhoffJ, SandinA, and BohmerFD. Regulation of protein tyrosine phosphatases by reversible oxidation. J Biochem, 150: 345–356, 2011.
46.
PantanoC, ReynaertNL, van der VlietA, and Janssen-HeiningerYM. Redox-sensitive kinases of the nuclear factor-kappaB signaling pathway. Antioxid Redox Signal, 8: 1791–1806, 2006.
47.
PollardJM, ReboucasJS, DurazoA, KosI, FikeF, PanniM, GrallaEB, ValentineJS, Batinic-HaberleI, and GattiRA. Radioprotective effects of manganese-containing superoxide dismutase mimics on ataxia-telangiectasia cells. Free Radic Biol Med, 47: 250–260, 2009.
48.
RabbaniZN, SpasojevicI, ZhangX, MoellerBJ, HaberleS, Vasquez-VivarJ, DewhirstMW, VujaskovicZ, and Batinic-HaberleI. Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin, MnTE-2-PyP(5+), via suppression of oxidative stress in a mouse model of breast tumor. Free Radic Biol Med, 47: 992–1004, 2009.
49.
SchaueD and McBrideWH. Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol, 12: 527–540, 2015.
50.
SokoloskyML, StadelmanKM, ChappellWH, AbramsSL, MartelliAM, StivalaF, LibraM, NicolettiF, DrobotLB, FranklinRA, SteelmanLS, and McCubreyJA. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget, 2: 538–550, 2011.
51.
SpasojevicI, WeitnerT, TovmasyanA, ShengH, MiriyalaS, LeuD, RajicZ, WarnerDS, ChairDS, HuangT-T, and Batinic-HaberleI. Pharmacokinetics, brain hippocampus and cortex, and mitochondrial accumulation of a new generation of lipophilic redox-active therapeutic, Mn(III) Meso Tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrin, MnTnBuOE-2-PyP5+, in comparison with its ethyl and N-hexyl analogs, MnTE-2-PyP5+ and MnTnHex-2-PyP5+. Free Radic Biol Med, 65: S132, 2013.
52.
TongQ, ZhuY, GalaskeJW, KosmacekEA, ChatterjeeA, DickinsonBC, and Oberley-DeeganRE. MnTE-2-PyP modulates thiol oxidation in a hydrogen peroxide-mediated manner in a human prostate cancer cell. Free Radic Biol Med, 101: 32–43, 2016.
TovmasyanA, GoYM, JonesDP, SpasojevicI, and Batinic-HaberleI. Redox proteomics of 4T1 breast cancer cell after treatment with MnTE-2-PyP5+/ascorbate system. Free Radic Biol Med, 100: S122, 2016.
TrachoothamD, AlexandreJ, and HuangP. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach?. Nat Rev Drug Discov, 8: 579–591, 2009.
57.
ValerieK, YacoubA, HaganMP, CurielDT, FisherPB, GrantS, and DentP. Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther, 6: 789–801, 2007.
58.
VolcicM, KarlS, BaumannB, SallesD, DanielP, FuldaS, and WiesmullerL. NF-kappaB regulates DNA double-strand break repair in conjunction with BRCA1-CtIP complexes. Nucleic Acids Res, 40: 181–195, 2012.
59.
WeitnerT, KosI, ShengH, TovmasyanA, ReboucasJS, FanP, WarnerDS, VujaskovicZ, Batinic-HaberleI, and SpasojevicI. Comprehensive pharmacokinetic studies and oral bioavailability of two Mn porphyrin-based SOD mimics, MnTE-2-PyP5+ and MnTnHex-2-PyP5+. Free Radic Biol Med, 58: 73–80, 2013.
60.
WeitzelDH, TovmasyanA, AshcraftKA, BoicoA, BirerSR, Roy ChoudhuryK, HerndonJ2nd, RodriguizRM, WetselWC, PetersKB, SpasojevicI, Batinic-HaberleI, and DewhirstMW. Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier. Environ Mol Mutagen, 57: 372–381, 2016.
61.
WeitzelDH, TovmasyanA, AshcraftKA, RajicZ, WeitnerT, LiuC, LiW, BuckleyAF, PrasadMR, YoungKH, RodriguizRM, WetselWC, PetersKB, SpasojevicI, HerndonJE2nd, Batinic-HaberleI, and DewhirstMW. Radioprotection of the brain white matter by Mn(III) n-Butoxyethylpyridylporphyrin-based superoxide dismutase mimic MnTnBuOE-2-PyP5+. Mol Cancer Ther, 14: 70–79, 2015.
62.
YeX, FelsD, TovmasyanA, AirdKM, DedeugdC, AllensworthJL, KosI, ParkW, SpasojevicI, DeviGR, DewhirstMW, LeongKW, and Batinic-HaberleI. Cytotoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate. Free Radic Res, 45: 1289–1306, 2011.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
